Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease (Q38075798)

28 August 2017

1 reference

title

Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease (English)

1 reference

28 August 2017

Walter H Hörl

1

1 reference

28 August 2017

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

2

1 reference

28 August 2017

117-130

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-012-0002-2

28 August 2017

0 references

cites work

Molecular biology of erythropoietin

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Erythropoietin-Associated PRCA: Still an Unsolved Mystery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Precipitation of a monoclonal antibody by soluble tungsten

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Quality of original and biosimilar epoetin products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Clinical safety of biosimilar recombinant human erythropoietins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Pure red cell aplasia due to follow-on epoetin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Polymorphisms of the insertion / deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Pathophysiology of anaemia: focus on the heart and blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Erythropoiesis-stimulating agents and pure red-cell aplasia: you can't fool Mother Nature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Follow-on biologics: challenges of the "next generation".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Development and characterization of novel erythropoiesis stimulating protein (NESP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Extended dosing of darbepoetin alfa in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Patients' perceptions of subcutaneous delivery of darbepoetin alfa by autoinjector prefilled pen versus prefilled syringe: a randomized, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Small peptides as potent mimetics of the protein hormone erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Recent advances in erythropoietic agents in renal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

New anemia therapies: translating novel strategies from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Bioimpedance analysis and cardiovascular status in pediatric patients on chronic hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-012-0002-2

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease

21 January 2018

1 reference

12 December 2020

Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis

1 reference

12 December 2020

Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys

1 reference

12 December 2020

Lessons from Eprex for biogeneric firms

1 reference

12 December 2020

Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial

1 reference

12 December 2020

Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly

1 reference

12 December 2020

Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients

1 reference

12 December 2020

Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease

1 reference

12 December 2020

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.

1 reference

12 December 2020

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 December 2020

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study

1 reference

12 December 2020

A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia

1 reference

12 December 2020

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)

1 reference

12 December 2020

Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients

1 reference

12 December 2020

Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease

1 reference

12 December 2020

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment

1 reference

12 December 2020

Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia

1 reference

12 December 2020

Not all new recombinant human erythropoietins are biosimilars

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease

1 reference

12 December 2020

C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease

1 reference

12 December 2020

Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia

1 reference

12 December 2020

The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trial

1 reference

12 December 2020

Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study

1 reference

12 December 2020

Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrations

1 reference

12 December 2020

Once-weekly epoetin alfa for treating the anemia of chronic kidney disease

1 reference

12 December 2020

Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-filled Syringes

1 reference

12 December 2020

Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl

1 reference

12 December 2020

Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial.

1 reference

12 December 2020

1 reference

12 December 2020

Chronic kidney disease anemia management: what should be done?

1 reference

12 December 2020

Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies

1 reference

12 December 2020

Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study

1 reference

12 December 2020

Erythropoiesis-stimulating agents--time for a reevaluation

1 reference

12 December 2020

Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials

1 reference

12 December 2020

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study

1 reference

12 December 2020

Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia

1 reference

12 December 2020

The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency

1 reference

12 December 2020

Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study

1 reference

12 December 2020

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia

1 reference

12 December 2020

An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months

1 reference

12 December 2020

Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease

1 reference

12 December 2020

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study

1 reference

12 December 2020

Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta

1 reference

12 December 2020

Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study

1 reference

12 December 2020

10.1007/S40265-012-0002-2

Identifiers

DOI

1 reference

PubMed ID

23338536

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23338536